|
AU2002308295B2
(en)
|
2001-03-12 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Steroids as agonists for FXR
|
|
EP1734970B1
(en)
|
2004-03-12 |
2014-12-31 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using fxr ligands
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
PT2040713E
(pt)
|
2006-06-27 |
2014-10-13 |
Intercept Pharmaceuticals Inc |
Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
|
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
EA020310B1
(ru)
*
|
2008-07-30 |
2014-10-30 |
Интерсепт Фармасьютикалз, Инк. |
Модуляторы рецептора tgr5 и их применение
|
|
ES2663948T3
(es)
|
2008-11-19 |
2018-04-17 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y método de uso de los mismos
|
|
WO2010062861A2
(en)
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
CA2744697C
(en)
|
2008-11-26 |
2016-06-21 |
Satiogen Pharmaceuticals, Inc. |
Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
|
|
US20110257139A1
(en)
|
2008-12-19 |
2011-10-20 |
Royal College Of Surgeons In Ireland |
Treatment of diarrhoea
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
ES2552657T3
(es)
*
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
ITRM20100329A1
(it)
*
|
2010-06-15 |
2011-12-16 |
Franco Baldelli |
Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
EP2525223A1
(en)
*
|
2011-05-19 |
2012-11-21 |
Universiteit Maastricht |
In vitro method for predicting in vivo genotoxicity of chemical compounds.
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013049595A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Ethicon Endo-Surgery, Inc. |
Methods and compositions of bile acids
|
|
AU2012328526B2
(en)
|
2011-10-28 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
US20130108573A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
|
|
NZ734451A
(en)
|
2012-06-19 |
2018-12-21 |
Intercept Pharmaceuticals Inc |
Preparation, uses and solid forms of obeticholic acid
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
AU2013334122B2
(en)
|
2012-10-26 |
2017-11-02 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
|
SG11201503697TA
(en)
*
|
2012-11-28 |
2015-06-29 |
Intercept Pharmaceuticals Inc |
Treatment of pulmonary disease
|
|
CA2912139C
(en)
*
|
2013-05-14 |
2021-04-20 |
Roberto Pellicciari |
11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
|
|
CN105636984A
(zh)
|
2013-06-13 |
2016-06-01 |
法斯特弗沃德制药有限公司 |
用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
|
|
JP6556129B2
(ja)
*
|
2013-08-01 |
2019-08-07 |
アメリカ合衆国 |
ファルネソイドｘ受容体の阻害剤及び医薬としての使用
|
|
SI3043865T1
(sl)
*
|
2013-09-11 |
2021-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
|
|
MX356006B
(es)
*
|
2013-10-18 |
2018-04-24 |
Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C |
Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
SG10201801654RA
(en)
|
2014-05-28 |
2018-04-27 |
Childrens Hospital Med Ct |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10407462B2
(en)
|
2014-05-29 |
2019-09-10 |
Bar Pharmaceuticals S.R.L. |
Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
|
|
MX2017003933A
(es)
|
2014-09-24 |
2017-06-30 |
Gilead Sciences Inc |
Metodos de tratamiento de la enfermedad hepatica.
|
|
WO2016045480A1
(zh)
*
|
2014-09-28 |
2016-03-31 |
上海源力生物技术有限公司 |
一种奥贝胆酸的制备方法
|
|
AU2015331848B2
(en)
|
2014-10-17 |
2022-03-03 |
Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
WO2016073767A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
TWI688571B
(zh)
|
2014-11-19 |
2020-03-21 |
英商Ｎｚｐ英國有限公司 |
化合物（四）
|
|
US10538550B2
(en)
|
2014-11-19 |
2020-01-21 |
NZP UK Limited |
6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
|
|
KR102526631B1
(ko)
|
2014-11-19 |
2023-04-27 |
엔제트피 유케이 리미티드 |
스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
|
|
US10131688B2
(en)
|
2014-11-19 |
2018-11-20 |
NZP UK Limited |
5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
|
|
JP2017535570A
(ja)
|
2014-11-26 |
2017-11-30 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
EA036404B1
(ru)
*
|
2015-02-06 |
2020-11-06 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции для комбинированной терапии
|
|
MX2017010376A
(es)
|
2015-02-11 |
2017-12-20 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
|
|
CA2981503C
(en)
|
2015-03-31 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
CR20170456A
(es)
|
2015-04-07 |
2018-06-13 |
Intercept Pharmaceuticals Inc |
Composiciones farmacéuticas para terapias combinadas
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
KR20180054770A
(ko)
*
|
2015-09-21 |
2018-05-24 |
인터셉트 파마슈티컬즈, 인크. |
간 재생 촉진 방법
|
|
EP3353189A4
(en)
|
2015-09-24 |
2019-06-19 |
Intercept Pharmaceuticals, Inc. |
METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
|
|
EP3981779A1
(en)
*
|
2015-10-07 |
2022-04-13 |
Intercept Pharmaceuticals, Inc. |
Farnesoid x receptor modulators
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
WO2017142895A1
(en)
*
|
2016-02-15 |
2017-08-24 |
Regents Of The University Of Minnesota |
Compositions and methods for treating clostridium associated diseases
|
|
US20170233431A1
(en)
*
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
US11419878B2
(en)
|
2016-03-28 |
2022-08-23 |
Intercept Pharmaceuticals, Inc. |
Medicine obtained by combining FXR agonist and ARB
|
|
WO2017180577A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
CN109415685B
(zh)
|
2016-05-05 |
2023-07-04 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CA3038534A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc. |
Crystalline forms of a bile acid derivative
|
|
EP4553082A3
(en)
|
2016-11-04 |
2025-08-20 |
Children's Hospital Medical Center |
Liver organoid compositions and methods of making and using same
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
CA3045023A1
(en)
|
2016-11-29 |
2018-06-07 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonylurea bile acid derivatives
|
|
EP3548507A4
(en)
|
2016-12-05 |
2020-07-15 |
Children's Hospital Medical Center |
COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
TW201832768A
(zh)
*
|
2017-03-07 |
2018-09-16 |
英特賽普醫藥品公司 |
治療癌症的方法
|
|
US20180256600A1
(en)
*
|
2017-03-07 |
2018-09-13 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
SI4122464T1
(sl)
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
CA3058754A1
(en)
|
2017-04-07 |
2018-10-11 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonyl carbamate bile acid derivatives
|
|
JP7248586B2
(ja)
|
2017-04-14 |
2023-03-29 |
チルドレンズ ホスピタル メディカル センター |
複数ドナー幹細胞組成物およびそれを作製する方法
|
|
WO2019023103A1
(en)
|
2017-07-24 |
2019-01-31 |
Intercept Pharmaceuticals, Inc. |
BILIARY ACID DERIVATIVES WITH ISOTOPIC MARKING
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
EP3694603B1
(en)
|
2017-10-10 |
2026-04-08 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
EP4678727A3
(en)
|
2018-07-26 |
2026-03-11 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US11208571B2
(en)
|
2018-08-08 |
2021-12-28 |
University Of Maryland, College Park |
Methods for nondestructive dispersing of carbon nanomaterials in water
|
|
CA3112026A1
(en)
|
2018-09-12 |
2020-03-19 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
US12600943B2
(en)
|
2019-02-01 |
2026-04-14 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
WO2020163201A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
SG11202113155XA
(en)
|
2019-05-30 |
2021-12-30 |
Intercept Pharmaceuticals Inc |
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
US12497597B2
(en)
|
2019-05-31 |
2025-12-16 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
AU2020283048A1
(en)
|
2019-05-31 |
2021-12-23 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
CN112142814B
(zh)
*
|
2019-06-26 |
2021-09-28 |
江苏吉贝尔药业股份有限公司 |
牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
|
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021144330A1
(en)
|
2020-01-15 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
KR20230154806A
(ko)
|
2021-01-14 |
2023-11-09 |
엔요 파마 |
Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
|
|
CN117320722A
(zh)
|
2021-04-28 |
2023-12-29 |
埃尼奥制药公司 |
使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
|
|
CN119950519B
(zh)
*
|
2025-01-07 |
2025-11-21 |
山东省海洋科学研究院(青岛国家海洋科学研究中心) |
奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用
|